Engineering the Yeast Saccharomyces cerevisiae for the Production of L-(+)-Ergothioneine

van der Hoek, Steven Axel; Darbani, Behrooz; Zugaj, Karolina E.; Prabhala, Bala Krishna; Biron, Mathias Bernfried; Randelovic, Milica; Medina, Jacqueline B.; Kell, Douglas B.; Borodina, Irina

Published in:
Frontiers in Bioengineering and Biotechnology

Link to article, DOI:
10.3389/fbioe.2019.00262

Publication date:
2019

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):
Engineering the Yeast Saccharomyces cerevisiae for the Production of L-(+)-Ergothioneine

Steven A. van der Hoek 1, Behrooz Darbani 1, Karolina E. Zugaj 1, Bala Krishna Prabhala 1†, Mathias Bernfried Biron 1, Milica Randelovic 1, Jacqueline B. Medina 1, Douglas B. Kell 1,2,* and Irina Borodina 1,*

† The Novo Nordisk Foundation Center for BioSustainability, Technical University of Denmark, Kongens Lyngby, Denmark,
2 Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom

INTRODUCTION

Ergothioneine (ERG) (2-mercaptolithistidine trimethylbetaine, IUPAC name (2S)-3-(2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)-2-(trimethylammonio)propanoate) is a naturally occurring antioxidant that can be found universally in plants and mammals (Melville, 1959); it possesses a tautomeric structure, but is mainly present in the thione form at physiological pH (Figure 1). Ergothioneine was discovered in 1909 in the ergot fungus Claviceps purpurea (Tanret, 1909), and its structure was determined 2 years later (Barger and Ewins, 1911). Subsequently, several other organisms were found to produce ergothioneine, including the filamentous fungus Neurospora crassa (Genghof et al., 1956), the yeast Schizosaccharomyces pombe (Pluskal et al., 2014), various actinobacteria (Genghof, 1970) including Mycobacterium smegmatis (Seebeck, 2010),
and in particular various basidiomycetes (mushrooms) (Genghof, 1970). Higher eukaryotes have been shown to contain ergothioneine (Melville, 1959; Halliwell et al., 2018), but to date no higher eukaryotes have been reported to biosynthesize ergothioneine. Plants are thought to take ergothioneine excreted by fungi up from the soil (Audley and Tan, 1968; Tan and Audley, 1968) or through symbiotic relationships (Park et al., 2010; Guo et al., 2016).

Ergothioneine is synthesized from one molecule of L-histidine (1), one molecule of L-cysteine (2), and 3 methyl groups donated by S-adenosyl-L-methionine (SAM, Figure 1). In M. smegmatis, the reaction sequence is catalyzed by five enzymes, encoded by egtA-E genes arranged in an operon (Sao Emani et al., 2018).

Four enzymes of the cluster EgtA, EgtB, EgtC, and EgtD catalyze four individual reactions that methylate L-histidine to form hercynine (3), convert L-cysteine to γ-L-glutamyl-L-cysteine (4), combine hercynine and γ-L-glutamyl-L-cysteine to generate γ-L-glutamyl-S-(hercyn-2-yl)-L-cysteine S-oxide (5) and produce the S-(hercyn-2-yl)-L-cysteine S-oxide (6, HCO). In fungi, the biosynthetic pathway is different, as a single enzyme Egt1 catalyzes the methylation of L-histidine (1) to give hercynine (3), which in turn is sulfoxidized with cysteine, producing HCO (6). HCO is converted into 2-(hydroxysulfanyl)hercynine (7) by a β-lyase, encoded by egtE in M. smegmatis and by the EGT2 gene in fungi. This compound is spontaneously reduced to ergothioneine (8, thiol form and 9, thione form). Comparing the bacterial and fungal pathway, it is important to note that the utilization of glutamate in the ergothioneine biosynthesis pathway also requires ATP. Recently, enzymes for the anaerobic production of ergothioneine were found in Chlorobium limicola.

**Abbreviations:** ERG, L-(+)-ergothioneine; HCO, S-(hercyn-2-yl)-L-cysteine S-oxide; PBS, phosphate-buffered saline; PI, propidium iodide; PLP, pyridoxal 5′-phosphate; SAM, S-adenosyl-L-methionine.
(Burn et al., 2017), where sulfur is directly transferred to the imidazole ring of hercynine to form ergothioneine (Leisinger et al., 2019). However, it is suggested that the anaerobic C-S bond formation is less efficient than its aerobic counterpart (Burn et al., 2017).

The antioxidant properties of ERG include the scavenging of free radicals and reactive oxygen species (Akanmu et al., 1991; Park et al., 2010; Ta et al., 2011) and the chelation of divalent metal ions (Hanlon, 1971). ERG has been shown to reduce oxidative damage in a variety of mammals (Deiana et al., 2004; Cheah and Halliwell, 2012). In humans, ERG is mainly accumulated in the liver, the kidneys, in erythrocytes, the eye lens, and in seminal fluid (Leone and Mann, 1951; Melville et al., 1954; Shires et al., 1997). It is transported by a specific transporter SLC22A4 (previously known as OCTN1) (Grundemann et al., 2005; Tschirka et al., 2018). The natural selection of such a transporter implies that ergothioneine is involved in the maintenance of health or the mitigation of disease, and it may even be a vitamin (Paul and Snyder, 2010). ERG has demonstrated effects in in vivo models of several neurodegenerative diseases (Link, 1995; Yang et al., 2012; Song et al., 2014), in ischemia reperfusion injury (Bedirli et al., 2004; Sakrak et al., 2008a,b), and in a variety of other diseases (Halliwell et al., 2018). Ergothioneine accumulates at sites of injury through the upregulation of SLC22A4/OCTN1 (Cheah et al., 2016; Tang et al., 2016). It is only slowly metabolized and excreted in humans (Cheah et al., 2017).

Because humans cannot produce ERG, they must obtain it through their diet. Although plants and animals also accumulate it to some degree, the main natural dietary source of ERG is basidiomycete mushrooms, where some species contain up to 7 mg of ERG per gram dry weight (Ey et al., 2007; Pfeiffer et al., 2011; Kalaras et al., 2017; Halliwell et al., 2018). Because of the beneficial effects and possible involvement of ERG in disease, ergothioneine may potentially prove its value in the global dietary supplement market, which was estimated at some $241.1 billion in 2019 (Wang et al., 2016). Currently, commercial ergothioneine is extracted from mushrooms or synthesized chemically.

Production of ergothioneine in microbial cell factories would provide a sustainable low-cost alternative to its current manufacturing processes. So far, fermentative ERG production has been reported in bacteria and filamentous fungi, including Methylobacterium aquaticum strain 22A (Alamgir et al., 2015), Aureobasidium pullulans (Fujitani et al., 2018), Rhodotorula mucilaginosa (Fujitani et al., 2018), cyanobacteria (Pfeiffer et al., 2011), Aspergillus oryzae (Takusagawa et al., 2019), and Escherichia coli (Oswa et al., 2018; Tanaka et al., 2019). Engineering of M. aquaticum with an extra copy of egtBD and the deletion of hutH (histidine-ammonia-lyase gene) lead to a strain that produced 7.0 mg ERG/g dry cell weight and 100 μg ERG/5 mL/7 days (Fujitani et al., 2018). In another study, multiple copies of EGT1 and EGT2 genes from N. crassa were integrated into the genome of the filamentous fungi A. oryzae. The engineered strain produced 231 mg ergothioneine per kg solid media (Takusagawa et al., 2019). In E. coli, at first 24 mg/L of secreted ERG was produced by expression of egtBCDE genes from M. smegmatis and optimization of the medium composition (Oswa et al., 2018). This was followed up by a study, in which the authors also expressed egtA and improved the strain by enhancing the cysteine and S-adenosyl methionine biosynthesis, as well as optimizing their medium further, to produce 1.3 g/L of ergothioneine in 216 h by fermentation (Tanaka et al., 2019). To the best of our knowledge, there are no reports on ergothioneine production in baker’s yeast, which is the preferred host for the production of nutraceuticals (Huang et al., 2008; Li and Borodina, 2014; Yuan and Alper, 2019). In this study we describe the metabolic engineering of the yeast Saccharomyces cerevisiae for the production of ergothioneine, reaching a titer of 0.6 g/L in fed-batch fermentation for 84 h.

### MATERIALS AND METHODS

#### Strains and Chemicals

*S. cerevisiae* strain CEN.PK113-7D (MATa URA3 HIS3 LEU2 TRP1 MAL2-8g SUC2) was a gift from Peter Köttet (Goethe University, Frankfurt/Main, Germany). *S. pombe* strain DSM 70572, obtained from Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Germany) was used for genomic DNA extraction. *E. coli* DH5α was used for cloning. Ergothioneine (catalog #E7521, ≥98% purity) was from Sigma-Aldrich, hercynine (catalog # H288900, ≥95% purity) was from Toronto Research Chemicals Inc. Simulated fed-batch medium components (EnPump 200) were from EnPresso GmbH (Germany). These components consist of a polysaccharide, in powder form, to add to the medium and an enzyme to release glucose from the polysaccharide. The rate of release is dependent on the enzyme concentration and allows for simulated carbon-limited fermentation.

#### Cloning

CpEgt1, MsEgtA, and MsEgtE were codon-optimized for *S. cerevisiae* using GeneGenie (Swainston et al., 2014), while the other genes were codon-optimized for *S. cerevisiae* using the codon-optimization tool provided by GeneArt. The genes were then ordered as synthetic gene strings from IDT DNA (MsEgtA) or GeneArt (all other synthetic gene strings). The only exceptions were two genes from *S. pombe*, which were isolated from genomic DNA. The DNA sequences of the genes are in **Supplementary Table 1**. All yeast strain construction was done using CRISPR/Cas9 and EasyClone-MarkerFree methods (Stoviczek et al., 2015; Jessop-Fabre et al., 2016). Correct cloning was validated by sequencing (Eurofins Genomics). Correct genome modification of yeasts was validated by colony PCR. The details on primers (**Supplementary Tables 2, 3**), biobricks (**Supplementary Table 4**), plasmids (**Supplementary Tables 5, 6**), and strains (**Supplementary Table 7**) are in **Supplementary Materials**.

#### Media and Small-Scale Cultivation Conditions

For *E. coli* selection, we used Lysogeny Broth (LB) with 100 mg/L ampicillin. For the selection of yeast strains, we used Yeast-Peptone-Dextrose (YPD) agar supplemented with 200 mg/L G418 for selection of Cas9 vector and 100 mg/L nourseothricin
for selection of the gRNA vector. Synthetic Complete (SC) medium was prepared using 6.7 g/L Yeast Nitrogen Base without amino acids from Sigma-Aldrich, 1.92 g/L Synthetic Drop-out supplement without histidine from Sigma-Aldrich and 76 mg/L histidine. For ERG production, yeast strains were cultivated in SC medium with 20 or 40 g/L glucose or with 60 g/L EnPump substrate (and 0.6% enzyme reagent) as carbon source. Precultures for cultivation experiments were prepared by inoculating a single colony of a strain into 5 mL of the medium used in the cultivation experiment and incubating at 30°C and 250 rpm for 24 h. The cultivations were performed in 24-deep-well plates from EnzyScreen, 3 mL of medium was used per well and the starting OD$_{600}$ was 0.5. The plates were incubated at 30°C with 250 rpm agitation.

**HPLC Analyses**

To determine the extracellular ergothioneine concentration, a 1 mL sample of fermentation broth was centrifuged at 3,000 × g for 5 min, the supernatant was moved into an HPLC vial and stored at −20°C until the analysis. The remaining cell pellet was washed twice with 1 mL MilliQ water and resuspended in 1 mL water. The extraction of intracellular ERG was performed according to Alamir et al. (2015) as following. The mixture was heated at 94°C for 10 min, vortexed at 1,600 rpm for 30 min using a DVX-2500 Multi-Tube Vortexer from VWR, and centrifuged at 10,000 × g for 5 min. The supernatant was transferred into an HPLC vial and stored at +4°C until analysis. The ERG concentrations were measured using a Dionex Ultimate 3000 HPLC system. Quantification was done based on standard curves using Chromleon software. Five microliter of sample was injected on a C18s UPLC T3 reversed-phase column (particle size 1.6 μm, pore size 120 Å, 2.1 × 150 mm). The flow rate was 0.3 mL/min, starting with 2.5 min of 0.1% formic acid, going up to 70% acetonitrile, 30% 0.1% formic acid at 3 min for 0.5 min, after which 100% 0.1% formic acid was run from min 4 to 9. Ergothioneine was detected at a wavelength of 254 nm. For analysis of bioreactor samples, we additionally quantified glucose, ethanol, pyruvate, and acetate concentrations by HPLC as described (Borodina et al., 2015).

**Fed-Batch Fermentation in Bioreactors**

A single colony from a YPD plate with ST8927 colonies (see below) was used to inoculate 5 mL of minimal media in 14 mL tube. The tube was incubated at 30°C and 250 rpm overnight. This overnight culture was transferred into 95 mL mineral medium in 500 mL baffled shake flask. The shake flask was then incubated overnight at 30°C and 250 rpm. Forty milliliters of this dense culture was used to inoculate 60 mL mineral medium in a new 500 mL baffled shake flask. Two shake flasks were prepared this way. These shake flasks were incubated at 30°C and 250 rpm for 4 h, the content of both shake flasks was combined, then centrifuged at 3,000 × g for 5 min. The supernatant was discarded, the pellet was washed with 25 mL sterile water, resuspended and centrifuged as before. The supernatant was discarded and the pellet resuspended in 10 mL mineral medium. This was then used to inoculate 0.5 L mineral medium in a 1 L Sartorius bioreactor. The starting OD$_{600}$ was 0.85. The stirring rate was set at 500 rpm, the temperature was kept at 30°C, and pH was maintained at pH 5.0 using 2 M KOH and 2 M H$_2$SO$_4$. The feeding was started as soon as CO$_2$ in the off-gas decreased by 50%. The initial feed rate was set at 0.6 g glucose h$^{-1}$, linearly increasing to 2.5 g glucose h$^{-1}$ over the span of 25.5 h. After that, the feed was set at a constant 1.4 g glucose h$^{-1}$ and 17.8 h later, the feeding rate was set to a constant 2.9 g glucose h$^{-1}$. The feed was stopped at 84 h. At 60.5 and 75.5 h, 2 g (NH$_4$)$_2$SO$_4$ was added as a sterile 100 g/L solution. At 60.5 and 73.5 h, 0.5 g MgSO$_4$ was added as a sterile 50 g/L solution, while 4 mL sterile trace metals solution and 2 mL sterile vitamin solution were added.

**Propidium Iodide Staining and Flow Cytometry Analysis**

Precultures were prepared by inoculating a single colony of strain ST7574, ST8461, and ST8654 into separate 14-mL tubes containing 5 mL of SC + 40 g/L glucose + 1 g/L His/Cys/Met and incubating at 30°C and 250 rpm for 24 h. Precultures were used to inoculate 25 mL SC + 40 g/L glucose + 1 g/L His/Cys/Met at a starting OD$_{600}$ of 0.5, which was incubated at 30°C and 250 rpm for 72 h. Every 24 h, a 1 mL sample of cell culture was taken from the yeast cultivation. This sample was washed two times with 1 mL phosphate-buffered saline (PBS), subsequently resuspended in 0.5 μg/mL propidium iodide (PI) in PBS and incubated for 20 min at room temperature in the dark. After incubation, the cells were washed two times with PBS and the percentage of PI stained cells was determined using a MACSQuant VYB system (Miltenyi Biotec). Data analysis was performed using the FlowJo software.

**Fluorescent Microscopy**

Precultures were prepared by inoculating a single colony into a 14 mL tube containing 5 mL YPD medium and incubating at 30°C and 250 rpm overnight. Overnight precultures of strains containing transporters linked to GFP and the control strain were used to inoculate 5 mL YPD medium in 14 mL tubes at OD$_{600}$ = 2 and were cultured at 30°C and 250 rpm for 5 h. One milliliter of the culture was harvested at 3,000 × g for 5 min. The cells were washed two times with PBS and subsequently pictures of the cells were taken using a Leica DM 400 B system, using Leica Application Suite V4 as image software.

**Medium Optimization**

A two-level fractional factorial based on the components of SC medium, with the levels high (+1, component 5-folds higher than original SC medium) and low (−1, component 5-folds lower than original SC medium), was used to determine the impact of individual components on the yield of ergothioneine. Two different stocks of all the individual components were prepared, one each for high and low concentrations and these were mixed together for all components to yield 64 different designed media. The design matrix for the fractional factorial grid has been attached (Supplementary Table 8). Precultures were prepared by inoculating a single colony of strain ST8461 into a 14 mL tube containing 5 mL SC medium and incubating at 30°C and 250 rpm overnight. Precultures were then used to inoculate 300 μL media in 96-deep-well plates from EnzyScreen at OD$_{600}$ = 0.1 in
duplicate for each different medium and incubated at 30°C and 225 rpm for 48 h. Samples for analysis were taken at 24 and 48 h.

**LC-MS Analysis for Medium Optimization**

Amounts of total ergothioneine were analyzed by LC-MS in MRM mode. The analysis was performed on a Bruker EVOQ (QqQ) coupled to UPLC. The LC part of the LC-MS/MS system consisted of a CTC autosampler module, a high pressure mixing pump and a column module (Advance, Bruker, Fremont, CA, USA). The injection volume was 1 µL. The chromatography was performed on a ZIC-HILIC column, 150 x 2.1 mm, 3 µm particle size (SeQuant, Merck Millipore), equipped with a 0.5 µ

**FIGURE 2** | Ergothioneine production in strains with different ERG pathway combinations on three variations of synthetic complete medium: (A) AA: 20 g/l glucose and 1 g/l of each L-His, L-Met, and L-Cys, (B) Glu: 40 g/l glucose, (C) FiT: 60 g/l EnPump substrate for slow glucose release to simulate fed-batch conditions.
van der Hoek et al. Engineering Yeast for Ergothioneine Production

FIGURE 3 | Ergothioneine production by yeast strains expressing human ERG transporter SLC22A4X or a putative ERG transporter from *M. smegmatis* on three variations of synthetic complete medium: (A) AA: 20 g/l glucose and 1 g/l of each L-His, L-Met, and L-Cys, (B) Glu: 40 g/l glucose, (C) FiT: 60 g/l EnPump substrate for slow glucose release to simulate fed-batch conditions, (D) Microscope images of yeast cells with ergothioneine transporters linked to GFP. To the left are Brightfield images and to the right GFP images. Top panels; ST8461, ergothioneine producing strain without transporter. Middle-top panels, ST8921, ergothioneine producing strain with a putative transporter from *Mycobacterium smegmatis* linked to GFP at the N-terminus. Middle panels, ST8922, ergothioneine producing strain with a putative transporter from *Mycobacterium smegmatis* linked to GFP at the C-terminus. Middle-bottom panels, ST8923, ergothioneine producing strain with a transporter from *Homo sapiens* linked to GFP at the C-terminus. Bottom panels, ST8924, ergothioneine producing strain with a transporter from *Homo sapiens* linked to GFP at the N-terminus.

Depth filter (KrudKatcher Classic, Phenomenex). Eluent A was 20 mM ammonium acetate, pH adjusted to 3.5 with formic acid in MilliQ water. Eluent B was acetonitrile. The total flow rate of eluent A and B was 0.4 mL/min. The isocratic elution was 30% A, and the total run time was 5 min. Retention time was 1.8 min for ergothioneine. The mass spectrometer was operated
RESULTS

Expression of Bacterial, Fungal, and Chimeric Biosynthetic Pathways Toward Ergothioneine in S. cerevisiae

The biosynthetic genes for ERG production were of both bacterial origin (M. smegmatis) and of fungal origin (C. purpurea, N. crassa, S. pombe). The Egt1 homologs in C. purpurea and S. pombe were identified by BLASTp using the sequence of Egt1 for N. crassa (Genbank accession: XP_956324.3). Similarly, Egt2 from S. pombe (Genbank accession: NP_595091.1) was used to find the Egt2 homologs in N. crassa and C. purpurea. Genbank accession numbers are provided in Supplementary Table 1. The genes were combined into sixteen pathway variants, where nine pathway variants were made of fungal genes, one pathway variant comprised bacterial genes only, and six variants contained both fungal and bacterial genes. The 16 yeast strains with different pathway variants were cultivated in three different media and the intra- and extracellular concentrations of ergothioneine were measured (Figure 2).

ERG titers were the highest in simulated fed-batch medium (up to 60 mg/L as compared to a maximum of 20 mg/L under batch conditions). Of the five best-performing pathway variants, four contained Egt1 from N. crassa and any other of the four enzymes catalyzing the 2nd enzymatic step (MsEgtE, NcEgt2, SpEgt2, or CpEgt2). The fifth contained CpEgt1 and MsEgtE. Curiously, CpEgt1 combined with any fungal Egt2 variants only produced ERG on the medium that contained high levels of histidine, cysteine and methionine (Figure 2A). We speculate that C. purpurea enzyme CpEgt1 has a lower affinity to one or several of the substrate(s) (histidine, SAM, cysteine) than the enzyme from N. crassa and hence ERG production was only feasible when the intracellular levels of the substrates was increased through supplementation in the medium. Overall, only 5–30% of the total ERG was secreted, while the rest was retained intracellularly. The strain ST8461, combining Egt1 from N. crassa and Egt2 from C. purpurea, was selected for further engineering.

Engineering Ergothioneine Transport

The concentration of ERG inside the cells can be estimated to be ~3.5 mM (for strain ST8461 on simulated fed-batch medium), which is 80-fold higher than in the broth. As M. smegmatis is known to secrete ergothioneine to levels up to 4 times the intracellular concentration (Sao Emani et al., 2013), we speculated that it may contain an equilibrative or effluxing ERG transporter. On the M. smegmatis genome, adjacent to the egtA-E operon, there is an open reading frame MSMEI_6084, encoding a protein annotated as a chloramphenicol exporter (Supplementary Figure 1). The protein has 12 transmembrane domains as predicted by Phyre2 (Kelley et al., 2015) (Supplementary Figure 2). We expressed codon-optimized variants of this gene and of the (normally concentrative) human ERG transporter SLC22A4 in strain ST8461 (Figure 3). However, there was no significant increase of intracellular or extracellular ERG production. To determine why neither transporter had an effect, we investigated their cellular localization by green fluorescent protein (GFP) tagging on the...
C- or N-termini (Figure 3). Interestingly, MsMEI_6084 mainly localized to the vacuolar membrane of S. cerevisiae, while human SLC22A4X was only weakly expressed and its localization could not be determined. Since neither of the transporters localized to the plasma membrane specifically, it can explain the lack of effect on ERG secretion.

**Engineering of Nitrogen Metabolism**

Both Tor1 (Hinnebusch, 2005; Ljungdahl and Daignan-Fornier, 2012) and Yih1 (Hinnebusch, 2005) inhibit Gcn2p, a positive regulator of GCN4. Deletion of either of these enzymes could lead to increased ERG production by increasing the amino acid pools in yeast. In Figure 4, we show the results of these alterations in the nitrogen metabolism of S. cerevisiae in different media. Yih1 deletion does not have an effect on the production of ergothioneine, while Tor1 only seems to lead to an increase in ERG under batch conditions. Since eventual ERG production is likely to be carried out under fed-batch conditions and neither of the deletions gave a positive effect under fed-batch conditions, we decided not to proceed with these genetic modifications.

**Supplementation of the Medium With Precursor Amino Acids**

To determine whether the supply of the three amino acids (L-histidine, L-cysteine, and L-methionine) that serve as precursors for ERG biosynthesis is limited, we cultivated several yeast strains with supplementation of 1 or 2 g/L of each of L-methionine, L-cysteine, and L-histidine. We chose two producing strains, ST8461 and ST8654, the latter containing the MsMEI_8064 gene.

---

**FIGURE 5** | Production of ergothioneine over time in the production strain with or without transporter in different media compositions. (A,D) Glu: SC + 40 g/l glucose, (B,E) AA: SC + 40 g/l glucose + 1 g/l His/Met/Cys, (C,F) AA2: SC + 40 g/l glucose + 2 g/l His/Cys/Met.
A non-producing strain ST7574 was used as a control. The experiments were performed in shake flasks and growth and ERG production were monitored over the course of 3 days (Figure 5). ERG accumulated primarily in the first 24 h of cultivation, which would correspond to the exponential growth on glucose, reaching ca. 16 mg/L in both producing strains, independent of any amino acid supplementation. The supplementation, however, affected the cellular growth, with the final OD being \(~46\) and \(52\)% lower when 1 or 2 g/L, respectively, of the amino acids were added. No degradation of ERG was observed; however surprisingly, there was a large variation in the intracellular vs. extracellular distribution of ERG depending on the addition of amino acids. Specifically, the addition of amino acids promoted the excretion of ERG in the stationary phase. We hypothesized that this was due to cell death because of the toxic effects of the added amino acids, in particular histidine (Watanabe et al., 2014) and cysteine (Kumar et al., 2006). Indeed propidium iodide staining of cells sampled every 24 h for 72 h, showed an increase in the fraction of dead cells from 9 to 70%, when amino acids were added at concentrations of 1 g/L (Supplementary Figure 3). Clearly, the concentrations of amino acids used were too high and hence we decided to undertake a more systematic medium optimization approach as described in the next section.

**Medium Optimization**

To perform optimization of medium composition, we chose a two-level fractional factorial design, where the concentrations each of the components of the synthetic complete medium were varied 5-fold (Figure 6, Supplementary Table 8). Strain ST8461 was cultured in SC medium (medium 65 in Figure 6) to provide a baseline for the ergothioneine production during the experiment with which to compare the performance of the other media. After 48 h, 63% of the designed media outperformed SC medium with regard to ERG titers. To be able to identify the best contributing components, the analysis was narrowed down to the eight top-performing media. Higher levels of arginine, histidine, methionine, and pyridoxine were present in these media, while we could find no compound that had its concentration reduced across most or all of these media. Even though cysteine is a precursor for ergothioneine, it is not universally increased across the different media. However, as methionine can be converted into both S-adenosyl methionine and cysteine by yeast, increased levels of methionine in the medium by itself could be enough for increasing ERG titers. Pyridoxine is a precursor for pyridoxal 5'-phosphate (PLP), which binds to EgtE to facilitate the conversion of HCO to 2-(hydroxysulfanyl)hercynine in a PLP-dependent manner (Song et al., 2015). Since CpEgt2 is the fungal equivalent of EgtE, it is likely that pyridoxine has a positive effect on ERG production through CpEgt2. Interestingly, higher concentrations of arginine also increased ergothioneine production. The amino acid metabolism of *S. cerevisiae* contains many degradation and bioconversion pathways for arginine to be converted into other amino acids (Ljungdahl and Daignan-Fornier, 2012), which might contribute to the increased ERG titers.

**Enhancing the Expression of Ergothioneine Biosynthetic Genes**

We recognized that the ERG-producing strain could be improved by increasing the expression of the ERG biosynthetic genes. We integrated an additional copy of NcEgt1 and/or CpEgt2 expression cosseted into ST8461 (Figure 7). An additional copy of NcEgt1 increased the titer by 80 and 20% for batch and
The effect of the integration of a second copy of Egt enzymes on the production of ergothioneine in the high producing strain in different media. Genomic alterations are shown as well. (A) Glu: SC + 40 g/l glucose (B) FIT: SC + 60 g/l EnPump substrate, 0.6% reagent A.

**FIGURE 7** The effect of the integration of a second copy of Egt enzymes on the production of ergothioneine in the high producing strain in different media. Genomic alterations are shown as well. (A) Glu: SC + 40 g/l glucose (B) FIT: SC + 60 g/l EnPump substrate, 0.6% reagent A.

Simulated fed-batch medium, respectively, while an additional copy of Egt2 did not increase the ergothioneine titer and even caused a decrease in simulated fed-batch medium. When additional copies of both genes were integrated, the total titer was increased by 25% on simulated fed-batch medium (ST8927). The marginal increase in titer indicates that the flux control of the pathway mainly resides elsewhere, either with the precursor supply or NcEgt1 and CpEgt2 may experience inhibition from ERG or its intermediates; this needs to be addressed through further strain engineering.

**Ergothioneine Production in Controlled Fed-Batch Fermentation**

Finally, the engineered ERG-producing ST8927 strain was cultivated in bioreactors under glucose-limited fed-batch conditions. Based on the medium optimization results from section Medium Optimization, we supplemented the fed-batch fermentation medium with arginine, histidine, methionine and pyridoxine. During the 84-h cultivation, 598 ± 18 mg/L erg was produced, of which 59% was extracellular, from 175.0 ± 3.5 g/L glucose (Figure 8). Next to that, a total of 3.2 g arginine, histidine, and methionine, as well as 192 mg pyridoxine was added through the starting medium and the feeding medium. The final dry weight of biomass was 55 ± 1 g/L, and as baker's yeast has a cell density of ~1.103 g/mL (Bryan et al., 2010), this brings the intracellular concentration of ERG to 17.7 mM, which is 11-fold higher than the extracellular concentration of 1.6 mM at the end of the fermentation. During the fermentation, at two points (after 48 and 72 h), the growth of the cells started stagnating. However, when we added extra (NH₄)₂SO₄, MgSO₄, trace metal solution, and vitamins, the cells began growing again. Most likely, the strain has an extra requirement for one or more of these components that was not found via the medium optimization, as the medium optimization was run under batch conditions, rather than fed-batch conditions in which yeast can reach much higher cell densities. Between 48 and 60 h, biomass concentration declined slightly and the ratio between the extra- and the intra-cellular ERG increased, which could be caused by increased cell death, similar as we observed upon the supplementation of high concentrations of amino acids (section Medium Optimization). The process performance could be improved by optimization of the medium composition, process physical parameters, and the feeding profile.

**DISCUSSION**

Ergothioneine is an antioxidant with many potential health benefits (Cheah and Halliwell, 2012; Ames, 2018; Halliwell et al., 2018). Furthermore, the interaction of ERG with metal ions (Hanlon, 1971) could conceivably play a role in the intracellular chaperoning of trace elements. Fermentation could provide an alternative and sustainable way for ergothioneine production compared to the current commercial processes. To this end, we have engineered *S. cerevisiae* for the production of ergothioneine, reaching levels of 0.6 g/L. As there are many different organisms that produce ergothioneine (Tanret, 1909; Genghof et al., 1956; Genghof and Vandamme, 1964; Genghof, 1970; Seebeck, 2010; Pfeiffer et al., 2011; Pluskal et al., 2014; Sheridan et al., 2016; Kalaras et al., 2017) (Supplementary Tables 9, 10), we have focused on the organisms in which genes for ergothioneine production were identified. Other heterologous or from different organisms could therefore also be tested in *S. cerevisiae* to potentially find better performing combinations than those described here.
In our ERG-producing strain, as much as 59% of the ergothioneine was detected extracellularly during fermentation, even though no ERG-specific transporter has been found in yeast so far. High intracellular concentrations of a product may inhibit its own biosynthesis or lead to product degradation (Kell et al., 2015; Borodina, 2019; Kell, 2019). We speculated that expressing an ERG-specific transporter might improve the secretion of ERG from the yeast cells. Expression of heterologous human ergothioneine transporter or a potential ergothioneine transporter from M. smegmatis did not improve the secretion, however the transporters were not well-expressed in the plasma membrane of S. cerevisiae.

The amino acid metabolism of S. cerevisiae is tightly regulated and its networks highly intertwined (Hinnebusch, 1988, 2005; Hinnebusch and Natarajan, 2002; Ljungdahl and Daignan-Fornier, 2012). Therefore, it would be easier to increase the total amino acid pool rather than increasing the individual amino acid pools. The general amino acid control of yeast is mainly regulated by GCN4 (Hinnebusch, 1988; Ljungdahl and Daignan-Fornier, 2012) and upregulation of GCN4 leads to transcription of the biosynthetic genes of various amino acids. As knock-out of Tor1 and Yih1 did not yield higher ERG titers, more difficult metabolic engineering of yeast for higher production of individual amino acids pools could lead to higher ERG titers. This is similar to the approach taken in E. coli, where use was made of a strain that was already overproducing cysteine (Osawa et al., 2018). In yeast, it is also possible to adopt several strategies that increase the amount of available SAM and/or methionine (Chen et al., 2016) to potentially improve ergothioneine production.

Additional to genetic manipulation, medium optimization has the benefit that it does not require extensive engineering of the strain to increase its production capabilities, while it gives a wealth of information on multiple components in the system that the strain might need for better production (Link and Weuster-Botz, 2011). However, supplementation of certain compounds can be expensive in an industrial setting and therefore the information gained can be used to lead further engineering efforts.

Ergothioneine production was only increased by a small amount following the integration of a second copy of both Egt genes. There are a number of potential explanations for this, such as a lack of precursors or [as is common (Cornishbowden et al., 1995)] possible feedback inhibition by pathway intermediates or products. Interestingly, integrating a second copy of NcEgt1 by itself, but not CpEgt2, did lead to an increase in ERG production. Indeed, in engineering A. oryzae (Takusagawa et al., 2019), it has been shown that hercynine accumulated following the integration of multiple copies of Egt1. This suggests that the second reaction catalyzed by the Egt1 enzyme, converting hercynine into HCO, tends to contribute more significantly to flux control.

Recently, another group managed to produce 1.3 g/L ergothioneine in using E. coli as a production organism (Tanaka et al., 2019). They used a cysteine hyperproducing strain, which was also engineered for increased methionine production. Additionally, their ERG production genes are on a plasmid which is present in the cells with 15–20 copy numbers. During fermentation, they supplemented the medium with histidine, methionine, thiosulfate, and pyridoxine, supporting the results.
found in our medium optimization experiment. While the titer obtained in *E. coli* was higher than in our fed-batch fermentation, the duration of the fermentation with *E. coli* was much longer at 216 h vs. the 84 h-fermentation using *S. cerevisiae* presented here.

The fungal pathway for the biosynthesis of ERG only encompasses two enzymes compared to the five of the bacterial pathway, and eliminates the need for the use of glutamate and energy in the form of ATP. While NcEgt1 has been produced in *E. coli* for *in vitro* studies of the enzyme (Hu et al., 2014), to the best of our knowledge, the fungal pathway has to date not been used for ERG production in *E. coli*. As we have shown *S. cerevisiae* is able to produce ergothioneine using the fungal pathway, the more energetically efficient biosynthesis pathway of fungi could lead to better product yield.

In conclusion, we produced ERG with a titer of 598 ± 18 mg/L in *S. cerevisiae* expressing fungal ERG biosynthesis pathway. As the first report of ergothioneine production in *S. cerevisiae*, our investigation into the impact of amino acid supplementation and the flux in the ERG pathway will help further ERG production efforts by yeast fermentation.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the manuscript/Supplementary Files.

**AUTHOR CONTRIBUTIONS**

IB and DK conceived the study, IB, SH, BP, and BD designed the experiments and analyzed the data. SH and KZ performed the strain screening and transporter experiments. MB performed the nitrogen metabolism alteration experiments. SH performed the amino acid supplementation time course. BP performed the medium optimization. The second copy integration experiments were performed by SH. The fed-batch fermentation was performed by SH, MR, and JM. SH, IB, and DK wrote the manuscript. IB and DK secured the funding and supervised the project.

**FUNDING**

This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 757384). The work has also been funded by the Novo Nordisk Foundation (grant number NNFI01CC1016517). Furthermore, funding from an Erasmus+ grant (grant agreement no. 2017-1-PL01-KA103-035590, university code PL WROCLAW04) has contributed to this work.

**ACKNOWLEDGMENTS**

The authors would like to thank Jolanda ter Horst for her help with the fed-batch fermentation experiment.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fbioe.2019.00262/full#supplementary-material

**REFERENCES**


**Conflict of Interest:** SH, BD, DK, and IB are named inventors on a European Patent application covering parts of the work described above.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 van der Hoek, Darbani, Zugaj, Prabhala, Biron, Randelovic, Medina, Kell and Borodina. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.